md1225,
The issue, Chris, is that everything is in a state of flux with regard to NWBO's opportunities and understanding of how to potentially increase patient pool size for Direct. They seem to be really focused on creating opportunities to get this right as fast as possible because they are sensing footsteps from the likes of Stanford and others. I believe they are putting the emphasis exactly where it is needed but I also believe they can now give us something about the Phase 3 trial with L with regard to timelines. Linda is a brilliant strategist when it comes to protecting this tech and this company and she will do whatever she needs to do on the fly to stay ahead of the game. I figured this out a long time ago without ever speaking to her. One day many more folks will come to this same conclusion. Best wishes.
News 
Market Data 
Discover 
